HealthCare Links
News archive
Bayer HealthCare supports diabetes projects in the Middle East, North Africa and Europe
Bayer HealthCare supports local projects under the “Excellence across Borders” program in order to improve care of people with diabetes. Among the projects is a Diabetic School Awareness Program in the Kingdom of Saudi Arabia, which is planned to start in autumn this year. » more
Positive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV)
Bayer HealthCare announced today positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) from the Phase 3 MYRROR study in myopic choroidal neovascularization (mCNV). » more
Bayer acquires majority interest in Conceptus
The Bayer Group has successfully completed its tender offer for the outstanding shares of Conceptus, Inc., Mountain View, California (NASDAQ:CPTS). » more
Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Currently there are no approved therapies specifically for radioactive iodine refractory differentiated thyroid cancer / Sorafenib (Nexavar®) significantly extended progression-free survival; median progression-free survival of 10.8 months, compared to 5.8 months with placebo / Results from pivotal Phase III DECISION trial presented in plenary session at Annual Meeting of the American Society of Clinical Oncology » more
Bayer European Regulatory update on Diane-35
Bayer HealthCare Pharmaceuticals welcomes the position of the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) of the European Medicines Agency (EMA) that the benefits of Diane-35 outweigh the risks for the treatment of moderate to severe acne related to androgen sensitivity and/or hirsutism (excessive unwanted growth of hair in women) in women of reproductive age. » more
Antitrust clearance obtained for Bayer's acquisition of Conceptus
Antitrust clearance from the US Federal Trade Commission (FTC) was obtained with respect to Bayer’s acquisition of Conceptus, Inc., Mountain View, California (NASDAQ:CPTS). The FTC raised no objection to the transaction within the relevant waiting period under US antitrust law, which expired yesterday. » more
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant » more
Johannes Schubmehl appointed CIO of Bayer HealthCare
Johannes Schubmehl (48) has been appointed Chief Information Officer (CIO) of Bayer HealthCare AG effective May 1, 2013. He succeeded Matthias Moritz, who had left the company at the end of March. » more
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) » more
Bayer European Regulatory update on Diane-35
Bayer HealthCare Pharmaceuticals welcomes the statement of the Product Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) affirming the positive benefit-risk profile of Diane-35 provided that several measures are implemented to minimize the risk of thromboembolism. » more
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
Bayer HealthCare has filed the oral investigational drug riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) for regulatory approval in Japan. » more
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Bayer signed an agreement Thursday to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines. » more
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types » more
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival » more
Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer
Bayer HealthCare today announced that the company has started to enroll patients in an international Phase III trial to evaluate the efficacy and safety of regorafenib for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib treatment. » more
Bayer HealthCare Demonstrates Successful Integration of the Company’s Largest-Ever Animal Health Acquisition
Bayer HealthCare is successfully integrating the recently acquired Teva Animal Health, Inc. by beginning the process of introducing products to the U.S. market under the Bayer brand. » more
Bayer to Present Data on Pulmonary Hypertension Research at the ATS International Conference 2013 in Philadelphia
Interim Analysis from Long-Term Extension Study PATENT-2 Phase III / Hemodynamic data and clinical correlation from CHEST-1 Phase III / New Data Sets from Pivotal PATENT-1 Phase III » more
Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc
Bayer's planned acquisition of Conceptus, Inc., based in Mountain View, California (NASDAQ:CPTS) is entering its next phase: Evelyn Acquisition Company, a subsidiary established by Bayer HealthCare LLC, Tarrytown, N.Y., for the purpose of the acquisition, is commencing today a cash tender offer for all the shares of Conceptus, Inc. at a price of US$31.00 per share. The total value of the transaction amounts to approximately US$ 1.1 billion (equivalent to EUR 852 million). » more
Bayer HealthCare enables new online resource to fight vector-borne diseases
New canine vector-borne disease webinar will support veterinarians to diagnose and treat vector-borne diseases which can also be transmitted to humans » more
Bayer HealthCare joins forces with Stroke Alliance for Europe to prevent Cardiovascular Disease
Ahead of the “Move for Health Day” (10 May) and the “European Stroke Day” (14 May), the Stroke Alliance for Europe (SAFE) and Bayer HealthCare jointly raise their voices that society cannot afford not to prevent cardiovascular diseases. » more
Bayer HealthCare Presents New Incubator Model for Biotech Startup Companies in Berlin
Second CoLaborator with dedicated lab space now at Bayer HealthCare Research & Development Center in Berlin / Shared lab space for promising life science startup companies to help them get their start » more
Bayer Provides Update on Phase II/III Trial of BAY 86-6150
Bayer HealthCare today announced that a Phase II/III trial evaluating the efficacy and safety of BAY 86-6150 in people with hemophilia A and hemophilia B with inhibitors has been discontinued. » more
Bayer to acquire Conceptus, Inc.
Bayer intends to broaden its portfolio in the field of contraception. Thus, Bayer HealthCare LLC has signed a merger agreement with Conceptus, Inc. (NASDAQ:CPTS), the California, U.S., based developer of the Essure® procedure, the leading non-surgical permanent birth control method, which is sold in the United States and other countries. » more
Bayer: Life Sciences off to a good start in anniversary year
New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience / Group sales up 2.1 percent to EUR 10,266 million / EBIT improves by 8.6 percent to EUR 1,771 million / EBITDA before special items increased by 0.4 percent to EUR 2,453 million / Net income rises 11.5 percent to EUR 1,160 million / Gratifying development in Emerging Markets / Group outlook for 2013 confirmed » more
First Patient Enrolled in Global Phase III Program Evaluating Bayer’s Amikacin Inhale in Intubated and Mechanically Ventilated Patients with Gram-negative Pneumonia
Bayer HealthCare announced today the successful enrolment of the first patient in a global Phase III program, INHALE, which will evaluate the efficacy and safety of Amikacin Inhale as an adjunctive therapy to the standard of care, intravenous antibiotics, in intubated and mechanically ventilated patients with Gram-negative pneumonia. Amikacin Inhale consists of a specially formulated Amikacin Inhalation Solution and a Pulmonary Drug Delivery System (PDDS). » more
Bayer HealthCare to broaden strategic alliance with German Cancer Research Center
Joint immunotherapy research laboratory at the National Center for Tumor Diseases (NCT) in Heidelberg / Operations at the joint laboratory scheduled to start in the middle of 2013 / Additional investments of up to €3 million per year » more
U.S. FDA Grants Priority Review to Bayer’s Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications
Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has granted priority review to the New Drug Application (NDA) for the oral investigational drug riociguat. » more
Bayer to Present New Data on Growing Oncology Pipeline
Bayer HealthCare (Bayer) will present latest preclinical and early clinical data on promising investigational compounds with new mechanisms at the American Association for Cancer Research (AACR) 104th Annual Meeting, April 6-10, 2013, in Washington, DC. The annual AACR meeting brings together the latest findings in all major areas of cancer research. » more
Bayer’s ATX-101 significantly and sustainably reduces unwanted fat under the chin
90% of patients maintained treatment success in two year follow up / Phase I pharmacokinetic data shows no clinically significant impact on lipid levels / Open-label study data from US trial to be presented at Innovation Session » more
Bayer’s Stivarga® (regorafenib) Tablets Approved in Japan for the Treatment of Advanced or Recurrent Colorectal Cancer
Bayer HealthCare announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Stivarga® (regorafenib) tablets for the treatment of patients with unresectable, advanced/recurrent colorectal cancer (CRC). » more
Bayer Healthcare
Bayer HealthCare Links
150 years of Bayer
Annual Report 2012
